J. Díez-Domingo Et Al. , "Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.," Human vaccines & immunotherapeutics , vol.18, no.1, pp.1981085, 2022
Díez-Domingo, J. Et Al. 2022. Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.. Human vaccines & immunotherapeutics , vol.18, no.1 , 1981085.
Díez-Domingo, J., Tinoco, J. C., Poder, A., Dinleyici, E. Ç., Nell, H., Salamanca De La Cueva, I., ... Ince, T.(2022). Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.. Human vaccines & immunotherapeutics , vol.18, no.1, 1981085.
Díez-Domingo, Javier Et Al. "Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.," Human vaccines & immunotherapeutics , vol.18, no.1, 1981085, 2022
Díez-Domingo, Javier Et Al. "Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.." Human vaccines & immunotherapeutics , vol.18, no.1, pp.1981085, 2022
Díez-Domingo, J. Et Al. (2022) . "Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.." Human vaccines & immunotherapeutics , vol.18, no.1, p.1981085.
@article{article, author={Javier Díez-Domingo Et Al. }, title={Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.}, journal={Human vaccines & immunotherapeutics}, year=2022, pages={1981085} }